(a)

ID	Age	Sex	TNM Stage	Treatment prior to PDX	Patient Tumour Source*	Germline Mutation
Q70P	47	M	IV	Gemcitabine, FOLFIRINOX	Primary	BRCA2 c.3167_3171delAAAA
O28	53	F	IIA	Gemcitabine - Cisplatin	Primary †	BRCA2 c.5946delT
O217	57	F	IIA	Gemcitabine - Cisplatin	Primary †	BRCA1 c.4327C>T
O232	50	M	IIB	Naïve	Primary	BRCA2 c.3166delC
Q392	61	F	IIB	Naïve	Primary	BRCA2 c.8677C>T
S145	37	M	IV	Naïve	Liver Metastasis †	BRCA1 c.68_69delAG
Q437	76	M	IIA	Naïve	Primary	BRCA2 c.5065_5066delGCinsAAA

* Whole genome sequenced and used to generate PDX for the preclinical trial

† PDX used for WGS when patient sample insufficient

(b)

ID	Age	Sex	TNM Stage	Treatment prior to PDX	Patient Tumour Source*	Germline Mutation
Q66	66	M	IIB	FOLFIRINOX	Primary	None
Q133	60	M	IIB	Naïve	Primary	None
Q155	70	M	IIB	Naïve	Primary	None

* Whole genome sequenced and used to generate PDX for the preclinical trial

Supplementary Table 1. Clinical characteristics of patients from whom patient-derived xenografts were generated and evaluated in the preclinical trial. (a) Clinical characteristics of g*BRCA*-mutated PDAC cases**. (b)** Clinical characteristics of HR-proficient PDAC cases**.**